Robert E. Waltermire - Jan 23, 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Senior VP, Chief Pharma Dev.
Signature
/s/ Brian J. Lynch**
Stock symbol
MDGL
Transactions as of
Jan 23, 2024
Transactions value $
$0
Form type
4
Date filed
1/25/2024, 05:50 PM
Previous filing
Jan 18, 2024
Next filing
May 23, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Award $0 +1.42K +27.73% $0.00 6.54K Jan 23, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (Right to Buy) Award $0 +2.14K $0.00 2.14K Jan 23, 2024 Common Stock 2.14K $229.00 Direct F2
transaction MDGL Market Stock Unit Award $0 +1.42K $0.00 1.42K Jan 23, 2024 Common Stock 1.42K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a grant of restricted stock units, which vest as to 25% of the shares on each of January 23, 2025, January 23, 2026, January 23, 2027 and January 23, 2028, provided the Reporting Person continues in service with the Issuer on each such date.
F2 The option vests as to 25% of the shares on the first anniversary of the date of grant (January 23, 2025) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three month period, provided the Reporting Person continues in service with the Issuer on each such date.
F3 Each market stock unit, which is performance-based, represents the contingent right to receive one share of common stock. The amount reported represents the target number of shares which may be issued upon vesting. The market stock units will vest upon certification concerning the Company's stock price performance measured against biotechnology stock index companies for the entire performance period ending December 31, 2026.

Remarks:

**As attorney-in-fact for Reporting Person